| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4be2300a741a69aa1b8bb47a88899f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-43 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11cffd89ab40c6eb6dd876754261f99a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad32ec58389fe0082a0834ee84a762d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bf4398dceea0466969319acf60ea59d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9159947fbc16c3a3a6590cd1a6edb7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e843cf5b682aa811ebfa4f8942298a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f416942a8c44e07fbafb5e2c18a21a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015f184ac56318d8bdf787861e1c3d52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_355519639235753bec2b3678bb4ff5e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5679a75f399ac43ab86a1d51a52b69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_660b7b52bd50ed29c5c125b29e93bf32 |
| publicationDate |
2015-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20150114107-A |
| titleOfInvention |
Pharmaceutical composition for Parkinson's Disease containing PON1 fusion protein |
| abstract |
The present inventors have found that PEP-1-PON1 fusion protein can protect dopamine neurons from oxidative stress in SH-SY5Y neuroblastoma cells and Parkinson's disease animal models. The PEP-1-PON1 fusion protein was confirmed to migrate into SH-SY5Y cells and into the substantia nigra of the brain by Western blot analysis. The PEP-1-PON1 fusion protein markedly inhibited the production of MPP + -induced reactive oxygen species and DNA fragmentation, resulting in the survival of SH-SY5Y cells. The neuroprotective effect is obtained by the effect of the PEP-1-PON1 fusion protein on the levels of apoptotic-mediator and apoptotic mediator. Furthermore, immunohistochemistry data using TH antibody and cresyl violet staining indicate that the PEP-1-PON1 fusion protein significantly protects dopamine cells in the substantia nigra against oxidative stress such as MPTP. Thus, the PEP-1-PON1 fusion protein can be used for the prophylactic and therapeutic use of Parkinson's disease. |
| priorityDate |
2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |